Trial · NCT00276744
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
NCT00276744, Phase 2, Terminated, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; results first posted 2018-08-27
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Individualized Drug Treatment for Treating Patients With Pancreatic Cancer. Trials, record NCT00276744. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00276744
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
- NCT number
- NCT00276744
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 249 participants, actual
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Conditions
- Pancreatic Cancer
- Interventions
- cetuximab, capecitabine, docetaxel, Erlotinib, Gemcitabine, Irinotecan, mitomycin C, rapamycin, conventional surgery
- First posted
- 2006-01-13
- Last updated
- 2018-10-24
- Results first posted
- 2018-08-27
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 6-month Overall Survival | 6 months | Percentage of patients survived at 6 months for patients whose tumors were xenografted and treated in the mouse when treated with the most active agent identified in that model |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | 6-month Overall Survival | 6 months | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| 6-month Overall Survival | Arm 1 | 53 | percentage of participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| PART A | STARTED | Arm 1 | 240 | |
| PART A | COMPLETED | Arm 1 | 142 | |
| PART A | NOT COMPLETED | Arm 1 | 98 | |
| PART B | STARTED | Arm 1 | 0 | |
| PART B | COMPLETED | Arm 1 | 0 | |
| PART B | NOT COMPLETED | Arm 1 | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Arm 1 | 0 | 0 |
| Total, other adverse events | Arm 1 | 0 | 0 |
| Total, serious adverse events | Arm 1 | 0 | 0 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 21135251 | DERIVED |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA006973 | Regional Oncology Research Center | NELSON, WILLIAM GEORGE | JOHNS HOPKINS UNIVERSITY | NATIONAL CANCER INSTITUTE | 1985 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00276744
GET https://conductscience.org/api/trials/v1/NCT00276744/registered